---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-001957"
form_type: "8-K"
ticker: "SLS"
cik: "0001390478"
company_name: "SELLAS Life Sciences Group, Inc."
filed_at: "2026-01-08T23:59:59+00:00"
generated_at: "2026-05-16T11:11:25.339667+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "medium"
source: SEC EDGAR
---

# SELLAS Life Sciences estimates $71.8M cash at Dec 31, 2025; $26.5M from warrant exercises post-quarter

## Summary
- Cash and cash equivalents estimate of $71.8M as of Dec 31, 2025 (unaudited, preliminary).
- Received ~$26.5M in proceeds from common stock warrant exercises subsequent to year-end.
- As of Jan 7, 2026, shares outstanding total 170,282,026.
- No other operational or financial results disclosed.

## SEC filing metadata
- accession: 0001104659-26-001957
- form_type: 8-K
- ticker: SLS
- cik: 0001390478
- company_name: SELLAS Life Sciences Group, Inc.
- filed_at: 2026-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: medium
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1390478/000110465926001957/0001104659-26-001957-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1390478/000110465926001957/tm262494d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-001957
- JSON: https://secwatch.observer/filing/0001104659-26-001957.json
- Plain text: https://secwatch.observer/filing/0001104659-26-001957.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.